
Pentecost has been busy for Veloxis Pharmaceuticals, which has entered two new license agreements for the Canadian as well as the Chinese and Taiwanese markets.
In Canada, the drug company Paladin Labs takes over the rights to Veloxis’ drug Envarsus XR, which is used for preventing organ rejection in kidney transplant patients.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app